Clinical Outcomes Associated with Polymyxin B Dose in Patients with Bloodstream Infections Due to Carbapenem-Resistant Gram-Negative Rods

There is significant variation in the use of polymyxin B (PMB), and optimal dosing has not been defined. The purpose of this retrospective study was to evaluate the relationship between PMB dose and clinical outcomes. We included patients with bloodstream infections (BSIs) due to carbapenem-resistan...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Nelson, Brian C., Eiras, Daniel P., Gomez-Simmonds, Angela, Loo, Angela S., Satlin, Michael J., Jenkins, Stephen G., Whittier, Susan, Calfee, David P., Furuya, E. Yoko, Kubin, Christine J.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2015
Matèries:
Clinical Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4604419/
https://ncbi.nlm.nih.gov/pubmed/26324272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00844-15
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars